La Jolla Pharmaceutical Company Company Profile (NASDAQ:LJPC)

About La Jolla Pharmaceutical Company (NASDAQ:LJPC)

La Jolla Pharmaceutical Company logoLa Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $642.01 million
  • Outstanding Shares: 22,123,000
Average Prices:
  • 50 Day Moving Avg: $28.55
  • 200 Day Moving Avg: $24.56
  • 52 Week Range: $14.63 - $39.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.34
  • P/E Growth: -0.46
Sales & Book Value:
  • Annual Revenue: $381,999.00
  • Price / Sales: 1,680.66
  • Book Value: $7.04 per share
  • Price / Book: 4.12
Profitability:
  • EBIDTA: ($84,240,000.00)
  • Net Margins: -6,921.47%
  • Return on Equity: -66.51%
  • Return on Assets: -59.13%
Debt:
  • Current Ratio: 12.00%
  • Quick Ratio: 12.00%
Misc:
  • Average Volume: 957,657 shs.
  • Beta: 0.58
  • Short Ratio: 2.35
 

Frequently Asked Questions for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

What is La Jolla Pharmaceutical Company's stock symbol?

La Jolla Pharmaceutical Company trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical Company's earnings last quarter?

La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced its quarterly earnings results on Thursday, April, 27th. The company reported ($1.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.34) by $0.08. La Jolla Pharmaceutical Company had a negative net margin of 6,921.47% and a negative return on equity of 66.51%. View La Jolla Pharmaceutical Company's Earnings History.

Where is La Jolla Pharmaceutical Company's stock going? Where will La Jolla Pharmaceutical Company's stock price be in 2017?

6 equities research analysts have issued 1-year target prices for La Jolla Pharmaceutical Company's stock. Their forecasts range from $34.00 to $57.00. On average, they anticipate La Jolla Pharmaceutical Company's share price to reach $45.20 in the next year. View Analyst Ratings for La Jolla Pharmaceutical Company.

What are analysts saying about La Jolla Pharmaceutical Company stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical Company stock:

  • 1. Cowen and Company analysts commented, "LJPC reported Q1 financials." (4/28/2017)
  • 2. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (4/26/2017)
  • 3. Chardan Capital analysts commented, "We believe the results are compelling and, based on the SPA, will likely result in LJPC-501 US approval. Recall from our 24 January 2017 note where we discussed the SPA, stating with regards to the primary endpoint," (3/2/2017)
  • 4. SunTrust Banks, Inc. analysts commented, "strong" ATHOS-3 data which implies LJPC-501 could be standard-of-care in last-line CRH.Suneja commented, "We believe today's highly favorable ATHOS-3 data (primary endpoint met; positive trend in mortality) are supportive of approval in CRH, which could be at least $500MM opportunity; an NDA filing is expected in 2H17 and full data are expected in 2017 at a major medical conference and publication in a "top-tier" journal. In our view, these results provide validation for LJPC's capital-efficient strategy of developing naturally occurring peptides with well-understood biological functions for life-threatening diseases. We reiterate our Buy rating and increase our NPV-derived PT to $57 from $38." (2/27/2017)

Are investors shorting La Jolla Pharmaceutical Company?

La Jolla Pharmaceutical Company saw a increase in short interest in May. As of May 15th, there was short interest totalling 5,105,190 shares, an increase of 0.7% from the April 28th total of 5,069,906 shares. Based on an average daily trading volume, of 217,974 shares, the days-to-cover ratio is presently 23.4 days.

Who are some of La Jolla Pharmaceutical Company's key competitors?

Who owns La Jolla Pharmaceutical Company stock?

La Jolla Pharmaceutical Company's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (15.55%), TANG CAPITAL PARTNERS LP (18.20%), FMR LLC (14.89%), Perceptive Advisors LLC (9.67%), Jennison Associates LLC (9.68%) and Janus Capital Management LLC (4.07%). Company insiders that own La Jolla Pharmaceutical Company stock include Dennis Mulroy, George F Tidmarsh, Kevin C Tang and Lakhmir S Chawla. View Institutional Ownership Trends for La Jolla Pharmaceutical Company.

Who sold La Jolla Pharmaceutical Company stock? Who is selling La Jolla Pharmaceutical Company stock?

La Jolla Pharmaceutical Company's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Janus Capital Management LLC, Morgan Stanley, Advisors Asset Management Inc., TIAA CREF Investment Management LLC, UBS Group AG, Nationwide Fund Advisors and Wells Fargo & Company MN. View Insider Buying and Selling for La Jolla Pharmaceutical Company.

Who bought La Jolla Pharmaceutical Company stock? Who is buying La Jolla Pharmaceutical Company stock?

La Jolla Pharmaceutical Company's stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Perceptive Advisors LLC, Redmile Group LLC, FMR LLC, Westfield Capital Management Co. LP, Tang Capital Management LLC, Boxer Capital LLC and Driehaus Capital Management LLC. Company insiders that have bought La Jolla Pharmaceutical Company stock in the last two years include Dennis Mulroy, George F Tidmarsh, Kevin C Tang and Lakhmir S Chawla. View Insider Buying and Selling for La Jolla Pharmaceutical Company.

How do I buy La Jolla Pharmaceutical Company stock?

Shares of La Jolla Pharmaceutical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of La Jolla Pharmaceutical Company stock cost?

One share of La Jolla Pharmaceutical Company stock can currently be purchased for approximately $29.02.

Analyst Ratings

Consensus Ratings for La Jolla Pharmaceutical Company (NASDAQ:LJPC) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $45.20 (55.75% upside)

Analysts' Ratings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Chardan CapitalSet Price TargetBuy$34.00LowView Rating Details
5/22/2017SunTrust Banks, Inc.Reiterated RatingBuy$57.00MediumView Rating Details
4/30/2017Noble FinancialReiterated RatingBuyLowView Rating Details
4/28/2017Cowen and CompanyReiterated RatingBuy$55.00LowView Rating Details
3/29/2017Jefferies Group LLCReiterated RatingBuy$40.00LowView Rating Details
2/28/2017JPMorgan Chase & Co.Reiterated RatingBuy$27.00 -> $40.00N/AView Rating Details
5/24/2016Lake Street CapitalInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Earnings by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Earnings History by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($1.34)($1.26)$0.17 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.20)($1.44)$0.16 million$0.09 millionViewN/AView Earnings Details
11/3/2016Q3($0.97)($1.23)$0.26 million$0.04 millionViewN/AView Earnings Details
8/8/2016Q2($0.99)($0.90)$0.25 million$0.25 millionViewN/AView Earnings Details
5/6/2016Q416($0.74)($0.96)$0.43 million$0.23 millionViewN/AView Earnings Details
2/25/2016Q4($0.72)($0.69)$0.41 millionViewN/AView Earnings Details
11/6/2015Q315($0.69)($0.70)$0.65 millionViewN/AView Earnings Details
8/7/2015Q215($0.61)($0.70)ViewN/AView Earnings Details
3/16/2015Q414($0.37)($0.45)ViewN/AView Earnings Details
11/12/2014Q314($0.42)($0.37)ViewN/AView Earnings Details
8/14/2014Q214($0.69)($0.63)ViewN/AView Earnings Details
4/30/2014Q1 2014($0.91)($0.93)ViewN/AView Earnings Details
3/31/2014($0.24)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
2017 EPS Consensus Estimate: ($4.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.39)($1.25)($1.32)
Q2 20172($1.26)($1.01)($1.14)
Q3 20172($1.22)($1.10)($1.16)
Q4 20172($1.19)($1.19)($1.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Insider Ownership Percentage: 26.43%
Institutional Ownership Percentage: 88.16%
Insider Trades by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Institutional Ownership by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Insider Trades by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/23/2017Kevin C TangDirectorBuy149,254$33.50$5,000,009.00View SEC Filing  
3/3/2017Dennis MulroyCFOBuy500$33.95$16,975.00View SEC Filing  
3/3/2017George F TidmarshCEOBuy3,000$34.17$102,510.00View SEC Filing  
3/3/2017Lakhmir S ChawlaInsiderBuy1,600$34.80$55,680.00View SEC Filing  
9/13/2016Kevin C TangDirectorBuy139,035$19.82$2,755,673.70View SEC Filing  
3/4/2016Kevin C TangDirectorBuy20,000$19.85$397,000.00View SEC Filing  
3/1/2016George F TidmarshCEOBuy2,000$16.57$33,140.00View SEC Filing  
9/28/2015Lakhmir S ChawlaInsiderBuy485$27.75$13,458.75View SEC Filing  
9/10/2015Kevin C TangDirectorBuy80,000$38.00$3,040,000.00View SEC Filing  
8/21/2015Kevin C TangDirectorBuy170,000$27.11$4,608,700.00View SEC Filing  
6/26/2015Kevin C TangDirectorBuy110,000$23.58$2,593,800.00View SEC Filing  
6/24/2015Kevin C TangDirectorBuy220,000$22.23$4,890,600.00View SEC Filing  
6/23/2015Kevin C TangDirectorBuy53,836$22.27$1,198,927.72View SEC Filing  
6/22/2015Kevin C TangDirectorBuy77,850$21.41$1,666,768.50View SEC Filing  
5/13/2015Kevin C TangDirectorBuy190,583$18.24$3,476,233.92View SEC Filing  
5/12/2015George F TidmarshCEOBuy4,000$18.37$73,480.00View SEC Filing  
12/15/2014Kevin C TangDirectorBuy232,343$12.84$2,983,284.12View SEC Filing  
12/11/2014George F TidmarshCEOBuy4,000$11.38$45,520.00View SEC Filing  
9/26/2014George F TidmarshCEOBuy2,000$9.35$18,700.00View SEC Filing  
9/26/2014Kevin C TangDirectorBuy169,555$9.14$1,549,732.70View SEC Filing  
9/25/2014Kevin C TangDirectorBuy30,500$9.17$279,685.00View SEC Filing  
9/24/2014Kevin C TangDirectorBuy95,000$9.10$864,500.00View SEC Filing  
9/18/2014George F TidmarshCEOBuy5,000$9.18$45,900.00View SEC Filing  
7/23/2014George F TidmarshCEOBuy19,000$10.50$199,500.00View SEC Filing  
5/21/2014George TidmarshCEOBuy12,000$7.37$88,440.00View SEC Filing  
4/14/2014George TidmarshCEOBuy8,000$9.53$76,240.00View SEC Filing  
2/7/2014George F TidmarshCEOBuy3,000$7.25$21,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Latest Headlines for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Source:
DateHeadline
americanbankingnews.com logo$170,000.00 in Sales Expected for La Jolla Pharmaceutical Company (LJPC) This Quarter
www.americanbankingnews.com - May 26 at 1:46 PM
americanbankingnews.com logoShort Interest in La Jolla Pharmaceutical Company (LJPC) Expands By 0.7%
www.americanbankingnews.com - May 25 at 11:05 AM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Given a $34.00 Price Target by Chardan Capital Analysts
www.americanbankingnews.com - May 23 at 6:58 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 23 at 4:16 PM
americanbankingnews.com logoSunTrust Banks, Inc. Reaffirms Buy Rating for La Jolla Pharmaceutical Company (LJPC)
www.americanbankingnews.com - May 22 at 8:22 PM
seekingalpha.com logoFull Phase 3 La Jolla Pharmaceutical Data Creates A Great Short Opportunity
seekingalpha.com - May 22 at 5:41 PM
benzinga.com logoLa Jolla Meets ATHOS-3 Trial Endpoints, Dispels Market Controversy In The Process - Benzinga
www.benzinga.com - May 22 at 10:20 AM
businesswire.com logoResults of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine - Business Wire (press release)
www.businesswire.com - May 22 at 10:20 AM
finance.yahoo.com logoMixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential
finance.yahoo.com - May 21 at 5:39 PM
finance.yahoo.com logoResults of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
finance.yahoo.com - May 21 at 5:39 PM
fool.com logoHere's Why La Jolla Pharmaceuticals Company Is Soaring - Motley Fool
www.fool.com - May 19 at 6:00 PM
finance.yahoo.com logoHere's Why La Jolla Pharmaceuticals Company Is Soaring
finance.yahoo.com - May 19 at 10:51 AM
finance.yahoo.com logoLa Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : May 19, 2017
finance.yahoo.com - May 19 at 10:51 AM
finance.yahoo.com logoImplied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
finance.yahoo.com - May 19 at 10:51 AM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Expected to Post Earnings of -$1.13 Per Share
www.americanbankingnews.com - May 1 at 9:00 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 1 at 6:48 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company's (LJPC) Buy Rating Reaffirmed at Noble Financial
www.americanbankingnews.com - April 30 at 7:35 AM
americanbankingnews.com logoPositive Press Coverage Somewhat Likely to Affect La Jolla Pharmaceutical Company (LJPC) Share Price
www.americanbankingnews.com - April 29 at 10:47 PM
americanbankingnews.com logoCowen and Company Reaffirms Buy Rating for La Jolla Pharmaceutical Company (LJPC)
www.americanbankingnews.com - April 29 at 1:01 AM
reuters.com logoBRIEF-La Jolla Pharmaceutical quarterly loss per share $1.26
www.reuters.com - April 28 at 7:14 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 28 at 6:43 PM
businesswire.com logoLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and ... - Business Wire (press release)
www.businesswire.com - April 28 at 9:33 AM
finance.yahoo.com logoLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
finance.yahoo.com - April 27 at 6:52 PM
marketbeat.com logoLa Jolla Pharmaceutical posts 1Q loss
marketbeat.com - April 27 at 6:48 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Likely to Impact La Jolla Pharmaceutical Company (LJPC) Stock Price
www.americanbankingnews.com - April 26 at 10:42 PM
finance.yahoo.com logoLa Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : April 24, 2017
finance.yahoo.com - April 24 at 7:03 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) to Post Q2 2017 Earnings of ($1.26) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - April 24 at 7:59 AM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Given Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 23 at 6:15 PM
finance.yahoo.com logoLa Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : April 21, 2017
finance.yahoo.com - April 21 at 10:05 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Impact La Jolla Pharmaceutical Company (LJPC) Stock Price
www.americanbankingnews.com - April 16 at 2:15 PM
americanbankingnews.com logo Brokerages Expect La Jolla Pharmaceutical Company (LJPC) to Post -$1.34 EPS
www.americanbankingnews.com - April 10 at 2:28 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 6 at 1:34 PM
streetinsider.com logoLa Jolla Pharmaceutical (LJPC) puts active after short report hits
www.streetinsider.com - April 4 at 8:20 AM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - March 29 at 10:16 PM
americanbankingnews.com logoKevin C. Tang Acquires 149,254 Shares of La Jolla Pharmaceutical Company (LJPC) Stock
www.americanbankingnews.com - March 27 at 10:25 PM
americanbankingnews.com logoLa Jolla Pharmaceutical Company (LJPC) Short Interest Update
www.americanbankingnews.com - March 26 at 7:23 AM
biz.yahoo.com logoLA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
biz.yahoo.com - March 24 at 9:18 AM
finance.yahoo.com logoLa Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 23 at 6:54 PM
finance.yahoo.com logo8:01 am La Jolla Pharm prices an underwritten public offering of approx 3.7 mln shares of common stock at $33.50/share for gross proceeds of $125 mln
finance.yahoo.com - March 23 at 6:54 PM
finance.yahoo.com logoLa Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock - Yahoo Finance
finance.yahoo.com - March 21 at 6:15 PM
streetinsider.com logoLa Jolla Pharmaceutical (LJPC) Plans $100M Common Stock Offering - StreetInsider.com
www.streetinsider.com - March 21 at 6:15 PM
streetinsider.com logoLa Jolla Pharmaceutical (LJPC) Plans $100M Common Stock Offering
www.streetinsider.com - March 21 at 12:00 PM
us.rd.yahoo.com logo4:01 pm La Jolla Pharm commences $100 mln common stock offering pursuant to its existing shelf registration statement
us.rd.yahoo.com - March 21 at 12:00 PM
reuters.com logoBRIEF-La Jolla Pharmaceutical Co announces proposed underwritten public offering of common stock
www.reuters.com - March 20 at 4:31 PM
seekingalpha.com logoLa Jolla Pharmaceutical readies $100M equity offering; shares down 4% after hours
seekingalpha.com - March 20 at 4:31 PM
us.rd.yahoo.com logoLa Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock
us.rd.yahoo.com - March 20 at 4:31 PM
nasdaq.com logoLa Jolla Pharmaceutical (LJPC) Has Broken Out To A New High For The Year
www.nasdaq.com - March 20 at 10:35 AM
americanbankingnews.com logoAnalysts’ Weekly Ratings Updates for La Jolla Pharmaceutical Company (LJPC)
www.americanbankingnews.com - March 14 at 9:58 AM
seekingalpha.com logoLaJolla Pharma under pressure on questions about LJPC-501's mortality benefit; shares slip 2%
seekingalpha.com - March 13 at 6:03 PM
zacks.com logoLa Jolla Pharmaceutical (LJPC) is in Overbought Territory: What's Next?
www.zacks.com - March 10 at 10:10 AM

Social

Chart

La Jolla Pharmaceutical Company (LJPC) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff